The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies find ...

$8.2 million in increased depreciation and amortization expense.$7.9 million in increased interest expense. FFO was $297.6 million, or $0.44 per diluted share, for the second quarter of 2025, compared ...

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that its president and chief executive officer, Jon Stonehouse, ...